Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Gross Margin (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Gross Margin data on record, last reported at 269.37% in Q4 2025.

  • For Q4 2025, Gross Margin fell 30592.0% year-over-year to 269.37%; the TTM value through Dec 2025 reached 3.79%, down 6574.0%, while the annual FY2025 figure was 3.79%, 3853.0% down from the prior year.
  • Gross Margin reached 269.37% in Q4 2025 per OCUL's latest filing, down from 87.8% in the prior quarter.
  • Across five years, Gross Margin topped out at 222.19% in Q4 2023 and bottomed at 269.37% in Q4 2025.
  • Average Gross Margin over 5 years is 48.01%, with a median of 86.68% recorded in 2025.
  • Peak YoY movement for Gross Margin: skyrocketed 44420bps in 2021, then tumbled -30592bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 91.96% in 2021, then soared by 201bps to 92.81% in 2022, then surged by 139bps to 222.19% in 2023, then crashed by -84bps to 36.55% in 2024, then tumbled by -837bps to 269.37% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 269.37% in Q4 2025, 87.8% in Q3 2025, and 85.56% in Q2 2025.